The content on this site is intended for healthcare professionals only
Dr Roberts presents the promising results from an early phase trial combining the anti-bcl-2 drug venetoclax with rituximab to eliminate chronic lymphocytic leukaemia (CLL) at a press conference at EHA 2015.
Read the news story for more.
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Advancements in paediatric Acute lymphoblastic leukemia management
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Choosing 1st line TKI Wisely in patients with CML
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
